CL2021003455A1 - Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida - Google Patents

Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida

Info

Publication number
CL2021003455A1
CL2021003455A1 CL2021003455A CL2021003455A CL2021003455A1 CL 2021003455 A1 CL2021003455 A1 CL 2021003455A1 CL 2021003455 A CL2021003455 A CL 2021003455A CL 2021003455 A CL2021003455 A CL 2021003455A CL 2021003455 A1 CL2021003455 A1 CL 2021003455A1
Authority
CL
Chile
Prior art keywords
methyl
compounds
thiazol
pyrimidin
trifluoro
Prior art date
Application number
CL2021003455A
Other languages
English (en)
Inventor
Antje Rottmann
Oliver Martin Fischer
Kai Thede
Simon Anthony Herbert
Ursula Ganzer
Andrea Rotgeri
Elisabeth Pook
Original Assignee
Bayer Ag
Bayer Pharma Antiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma Antiengesellschaft filed Critical Bayer Ag
Publication of CL2021003455A1 publication Critical patent/CL2021003455A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invendón cubre compuestos inhibidores de P2X3 de la fórmula general (1), R, O CH N fNNF OR E en la cual R 1y R2son como se definen en la presente, métodos para preparar dichos compuestos, compuestos intermediarios útiles para preparar dichos compuestos, composiciones y combinaciones farmacéuticas que comprenden dichos compuestos, y el uso de dichos compuestos para manufacturar composicIones farmacéuticas para el tratamiento o la profilaxis de enfermedades, en particular de trastornos neurogénicos, como un único agente o en combinación con otros ingredientes activos.
CL2021003455A 2019-06-27 2021-12-23 Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida CL2021003455A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19182797.1A EP3757103A1 (en) 2019-06-27 2019-06-27 Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases

Publications (1)

Publication Number Publication Date
CL2021003455A1 true CL2021003455A1 (es) 2022-08-05

Family

ID=67105828

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021003455A CL2021003455A1 (es) 2019-06-27 2021-12-23 Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida

Country Status (19)

Country Link
US (1) US20230013419A1 (es)
EP (2) EP3757103A1 (es)
JP (1) JP2022538270A (es)
KR (1) KR20220027860A (es)
CN (1) CN114026086A (es)
AU (1) AU2020303269A1 (es)
BR (1) BR112021024325A2 (es)
CA (1) CA3145204A1 (es)
CL (1) CL2021003455A1 (es)
CO (1) CO2021017435A2 (es)
CR (1) CR20210686A (es)
EC (1) ECSP21088111A (es)
IL (1) IL289161A (es)
JO (1) JOP20210338A1 (es)
MA (1) MA56383A (es)
MX (1) MX2021015853A (es)
PE (1) PE20220219A1 (es)
PH (1) PH12021553202A1 (es)
WO (1) WO2020260463A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE058009T2 (hu) 2014-12-09 2022-06-28 Bayer Ag 1,3-Tiazol-2-il szubsztituált benzamid-származékok
AU2021282039A1 (en) * 2020-05-25 2022-12-01 The National Institutes of Pharmaceutical R&D Co., Ltd. Arylformamide compound and preparation method and medical use thereof
WO2022063205A1 (zh) * 2020-09-24 2022-03-31 中国医药研究开发中心有限公司 芳基甲酰胺类化合物及其制备方法和医药用途
WO2022068930A1 (zh) * 2020-09-30 2022-04-07 武汉人福创新药物研发中心有限公司 苯甲酰胺类化合物及其用途
CN114591317A (zh) * 2020-12-04 2022-06-07 武汉人福创新药物研发中心有限公司 P2x3抑制剂及其用途
WO2023185931A1 (zh) * 2022-03-29 2023-10-05 人福医药集团股份公司 一种p2x3抑制剂化合物及其盐、多晶型和用途
TW202525285A (zh) * 2023-12-29 2025-07-01 大陸商人福醫藥集團股份公司 Ｐ２ｘ３受體拮抗劑的固體分散體及其製備方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2091927B1 (en) * 2006-11-09 2011-07-20 F. Hoffmann-La Roche AG Thiazole and oxazole-substituted arylamides
US8501933B2 (en) * 2006-11-09 2013-08-06 Roche Palo Alto Llc Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
CA2705138A1 (en) * 2007-11-08 2009-05-14 Sirtris Pharmaceuticals, Inc. Solubilized thiazolopyridines
MX2010009561A (es) * 2008-02-29 2010-09-24 Renovis Inc Compuestos amida, composiciones y usos de los mismos.
EP2379518B1 (en) * 2008-12-16 2014-05-07 F. Hoffmann-La Roche AG Thiadiazole-substituted arylamides
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
HUE058009T2 (hu) * 2014-12-09 2022-06-28 Bayer Ag 1,3-Tiazol-2-il szubsztituált benzamid-származékok
US10183937B2 (en) * 2014-12-09 2019-01-22 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
WO2019219674A1 (en) * 2018-05-15 2019-11-21 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
CA3100096A1 (en) * 2018-05-15 2019-11-21 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization

Also Published As

Publication number Publication date
MX2021015853A (es) 2022-02-03
CR20210686A (es) 2022-02-09
CN114026086A (zh) 2022-02-08
PH12021553202A1 (en) 2022-10-24
JOP20210338A1 (ar) 2023-01-30
EP3757103A1 (en) 2020-12-30
EP3990453A1 (en) 2022-05-04
CA3145204A1 (en) 2020-12-30
US20230013419A1 (en) 2023-01-19
JP2022538270A (ja) 2022-09-01
IL289161A (en) 2022-02-01
PE20220219A1 (es) 2022-02-02
MA56383A (fr) 2022-05-04
BR112021024325A2 (pt) 2022-01-11
KR20220027860A (ko) 2022-03-08
AU2020303269A1 (en) 2022-02-03
WO2020260463A1 (en) 2020-12-30
ECSP21088111A (es) 2022-01-31
CO2021017435A2 (es) 2022-01-17

Similar Documents

Publication Publication Date Title
CL2021003455A1 (es) Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida
JOP20220131A1 (ar) مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة
CL2022002919A1 (es) Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune
ECSP19030002A (es) 1,2,4-triazolonas 2,4,5-trisustituidas
CO2019014484A2 (es) Nuevos derivados de azaquinolina
UY37845A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
MX2020013853A (es) Compuestos innovadores.
CU20170077A7 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos, composiciones y combinaciones que lo comprende
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
EA202090448A1 (ru) Дигидрооксадиазиноны
PH12020550494A1 (en) Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors
MY197561A (en) Composition for increasing expression of pgc-1?
AR117844A1 (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina
MX2019014436A (es) Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa.